Genmab A/S (NASDAQ: GMAB) announced results from its pivotal Phase 3 EPCORE FL-1 study showing that EPKINLY (epcoritamab-bysp) combined with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE